Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.
- Entered Analytical Validation phase for FDA submission
- Staged manufacturing program underway with Bio-Techne
- U.S. reimbursement pathway established using CPT code 81599
- Cash reserves of A$6.2 million support ongoing milestones
- Clinical Validation preparations progressing on schedule
Analytical Validation Marks Key Regulatory Step
Cleo Diagnostics (ASX:COV) is pushing ahead with its ovarian cancer blood test, having entered the formal Analytical Validation (AV) phase following completion of assay development and manufacturing preparation. This regulatory milestone initiates a structured FDA validation framework designed to generate the analytical data necessary for the company's planned 510(k) submission targeted for the first half of 2027. The AV phase includes testing three independently manufactured batches to demonstrate assay reproducibility and manufacturing consistency, a critical step to de-risk the transition from development to commercial-scale production.
Manufacturing Partnership with Bio-Techne Progresses
The company commenced a staged manufacturing program with Bio-Techne Corporation in late April, producing clinical-grade test kits essential for AV and subsequent regulatory submission. This collaboration leverages Bio-Techne’s Ella™ platform, with the first validation batch expected imminently. Cleo has also commissioned three additional Ella™ instruments to support testing capacity. The manufacturing program's progress materially reduces execution risk ahead of FDA submission and supports consistency in assay performance.
U.S. Reimbursement Strategy Established for Early Market Entry
In parallel with regulatory progress, Cleo has established a U.S. reimbursement pathway using the miscellaneous CPT code 81599, enabling the company to commence billing and real-world utilisation data capture immediately after FDA clearance. This approach benchmarks reimbursement levels against similar multi-biomarker diagnostic tests, which typically receive payments between US$500 and US$900 per test depending on the payer. The company plans to pursue a dedicated CPT code subsequently to support broader coverage and commercial scale.
Financial Position Supports Upcoming Milestones
As at 30 June 2026, Cleo held cash reserves of A$6.2 million, providing sufficient runway to fund ongoing clinical, regulatory, and commercial activities. The June quarter saw operating cash outflows of A$1.67 million, primarily driven by research and development expenditure. Payments to related parties, including executive and non-executive directors, totalled A$198,000. The company’s cash position is a critical buffer as it advances toward FDA submission and market launch.
Clinical Validation Preparations Underway
Following AV, Cleo will progress to Clinical Validation (CV), the final study phase supporting FDA submission. CV will analyse samples from the pivotal U.S. clinical trial, alongside confounding condition and healthy control samples, to build a comprehensive clinical evidence package. Preparations for CV include engaging an external laboratory and finalising study protocols, indicating that the company remains on track to meet its regulatory timeline, subject to manufacturing schedule adherence.
Bottom Line?
Cleo’s advancement into analytical validation and establishment of a U.S. reimbursement code set the stage for FDA submission and early market access, but execution risks remain tied to manufacturing timelines and regulatory approval.
Questions in the middle?
- Will Bio-Techne’s manufacturing timeline sustain the planned FDA submission date?
- How quickly can Cleo secure a dedicated CPT code to expand reimbursement coverage?
- What real-world data will emerge from early market utilisation post-FDA clearance?